JOSEPH L. JORIZZO, M.D.; W. MITCHELL SAMS Jr., M.D.; BRIAN V. JEGASOTHY, M.D.; ALAN J. OLANSKY, M.D.
Four adult patients with chronic mucocutaneous candidiasis were studied to establish a possible role for cimetidine as an immunomodulator. These patients had negative baseline in-vivo and in-vitro cell-mediated immune response to candida antigen as measured by intradermal skin tests, lymphocyte transformation, and leukocyte migration inhibitory factor production to candida antigen. Patients were given a 4-week course of cimetidine, 300 mg by mouth, four times daily. Subsequently four of four patients developed strong (> 15 mm) intradermal skin test reactions, and two of four patients produced leukocyte migration inhibitory factor to candida antigen. Skin tests and leukocyte migration inhibitory factor production reverted to baseline negative values when repeated 4 weeks after discontinuation of therapy. After 4 additional weeks on cimetidine, four of four patients showed strong positive skin tests and leukocyte migration inhibitory factor production to candida antigen. Lymphocyte transformation was not affected by therapy.
JOSEPH L. JORIZZO, W. MITCHELL SAMS, BRIAN V. JEGASOTHY, ALAN J. OLANSKY. Cimetidine as an Immunomodulator: Chronic Mucocutaneous Candidiasis as a Model. Ann Intern Med. 1980;92:192–195. doi: 10.7326/0003-4819-92-2-192
Download citation file:
Published: Ann Intern Med. 1980;92(2_Part_1):192-195.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use